1. Safety and Cross-Variant Immunogenicity of a Three-dose COVID-19 mRNA Vaccine Regimen in Kidney Transplant Recipients
- Author
-
Filippo Massa, PhD, Marion Cremoni, MD, Alexandre Gérard, MD, Hanen Grabsi, Lory Rogier, Mathilde Blois, MD, Chloé Couzin, MD, Nadia Ben Hassen, Matthieu Rouleau, PhD, Susana Barbosa, PhD, Emanuela Martinuzzi, PhD, Julien Fayada, Ghislaine Bernard, MD-PhD, Guillaume Favre, MD-PhD, Paul Hofman, MD-PhD, Vincent L.M. Esnault, MD-PhD, Cecil Czerkinsky, MD-PhD, Barbara Seitz-Polski, MD-PhD, Nicolas Glaichenhaus, PhD, and Antoine Sicard, MD-PhD
- Subjects
COVID-19 ,mRNA vaccine ,variants of concern, kidney transplantation ,Immunogenicity ,Medicine ,Medicine (General) ,R5-920 - Abstract
Background: The immunogenicity of a two-dose mRNA COVID-19 vaccine regimen is low in kidney transplant (KT) recipients. Here, we provide a thorough assessment of the immunogenicity of a three-dose COVID-19 vaccine regimen in this population. Methods: We performed a prospective longitudinal study in sixty-one KT recipients given three doses of the BNT162b2 COVID-19 vaccine. We performed semi-structured pharmacovigilance interviews and monitored donor-specific antibodies and kidney function. We compared levels of anti-spike IgG, pseudo-neutralization activity against vaccine homologous and heterologous variants, frequency of spike-specific interferon (IFN)-γ-secreting cells, and antigen-induced cytokine production 28 days after the second and third doses. Findings: Reactions to vaccine were mild. One patient developed donor-specific anti-HLA antibodies after the second dose which could be explained by non-adherence to immunosuppressive therapy. Spike-specific IgG seroconversion raised from 44·3% (n=27) after the second dose to 62·3% (n=38) after the third dose (p
- Published
- 2021
- Full Text
- View/download PDF